Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award

  • Martine Clozel was selected for the Prix Suisse award for her contribution to research, science, and medicine and was presented with the Prix Suisse by the National Council President Irène Kälin
  • The Prix Suisse is an annual award presented by the non-profit organization Initiative Switzerland to individuals who have made outstanding contributions to Switzerland

Allschwil, Switzerland – November 13, 2022
Idorsia Ltd (SIX: IDIA) today announced that Chief Scientific Officer Martine Clozel was honored by the organization Initiative Switzerland with the annual Prix Suisse Award at an award ceremony in the Kursaal Bern on Saturday, 12 November. The Prix Suisse is a national award and represents the highest distinction for outstanding achievements in Switzerland and was presented to Martine by Irène Kälin, The President of the National Council of Switzerland.

In her introduction, Irène Kälin commented:
“Martine Clozel would have deserved an award for every single facet of her diverse work. The sum of all her work is greater than what she has achieved as a doctor, entrepreneur, and researcher in the respective fields. An incredibly impressive woman."

Martine Clozel is a Founder and Chief Scientific Officer at Idorsia. Previously, she had co-founded Actelion alongside Jean-Paul Clozel, Walter Fischli, and Thomas Widmann. Martine has published more than 150 peer-reviewed articles, authored more than 40 patent applications, and co-authored several books in the areas of endothelin and orexin research and their applications. The research from Martine and the teams at Actelion, and then Idorsia, has resulted in several new treatments for patients. After years of research, innovative life changing drugs are now available, in the fields of pulmonary arterial hypertension, multiple sclerosis, the prevention of the cerebral consequences of aneurysmal rupture, and chronic insomnia. In 2008, Martine was awarded "Chevalier dans l'Ordre de la Légion d'Honneur" in France. In 2015, she was awarded the Tomoh-Masaki Prize for her achievements and contributions in the field of endothelin. The École polytechnique fédérale de Lausanne EPFL awarded her an honorary doctorate in 2018.

Accepting this award, Martine Clozel said:
"This year’s Prix Suisse is a great honor, and to my mind it is a tribute to science, to research, to all scientists and researchers and their perseverance to discover new mechanisms, new molecules, ultimately develop new medicines that can help those living with diseases. And, as we have found with both Actelion and now Idorsia, Switzerland is a great place for startups and developing businesses, as the country offers excellent conditions that drive innovation, talent, and technology.”

About the Prix Suisse
This award is presented each year to a Swiss personality who has achieved remarkable things for Switzerland both now and in the past through a combination of audacity, creativity, innovation, hard work and perseverance. They will act as role models for present and future generations. Last year’s award recipient, Peter Spuhler, an entrepreneur, investor, and innovator, who, through courage, willingness to take risk, and hard work, grew the Stadler Rail Group into an internationally renowned and innovative business.

Stefan Linder, the Head of Initiative Switzerland, commented:
"Martine Clozel is not only a doctor and scientist, but also a successful company founder whose work around drug discovery has enabled several new medicines to emerge from Switzerland. Her work is changing the lives of hundreds of thousands of patients around the world. Martine Clozel is an inspiration and role model for all people in Switzerland. Accordingly, we are delighted to honor her with this year's Prix Suisse."

Notes to the editor

About Initiative Switzerland
As a private funding agency, Initiative Switzerland supports innovative ideas and projects in all parts and language regions of Switzerland. In doing so, it specifically promotes competitiveness and prosperity in Switzerland. With its activities and projects, it wants to contribute to Switzerland's ability to sustainably secure its top global position and innovative strength. Initiative Switzerland is financed by F.G. Pfister Holding AG and through the dividends generated by the holding company. The "Prix Suisse", which is awarded annually, honors a personality who has made outstanding contributions to Switzerland and distinguishes himself or herself through courage, creativity and innovation.

The "Initiative Switzerland" is headed by Stefan Linder, co-founder, long-standing CEO and delegate of the Swiss Economic Forum.

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,200 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.